Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo

Spiegel, A.M. (1996) Defects in G protein-coupled signal transduction in human disease. A. Rev. Physiol., 58, 143–170.

Morello, J.P., Petaja-Repo, U.E., Bichet, D.G. and Bouvier, M. (2000) Pharmacological chaperones: a new twist on receptor folding. Trends Pharmac. Sci., 21, 466–469.

Schöneberg, T., Schulz, A. and Gudermann, T. (2002) The structural basis of G-protein-coupled receptor function and dysfunction in human diseases. Rev. Physiol. Biochem. Pharmac., 144, 143–227.

Mankin, A.S. and Liebman, S.W. (1999) Baby, don't stop! Nat. Genet., 23, 8–10.

Howard, M., Frizzell, R.A. and Bedwell, D.M. (1996) Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat. Med., 2, 467–469.

Barton-Davis, E.R., Cordier, L., Shoturma, D.I., Leland, S.E. and Sweeney, H.L. (1999) Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J. Clin. Invest., 104, 375–381.

Bedwell, D.M., Kaenjak, A., Benos, D.J., Bebok, Z., Bubien, J.K., Hong, J., Tousson, A., Clancy, J.P. and Sorscher, E.J. (1999) Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat. Med., 3, 1280–1285.

Wildin, R.S., Antush, M.J., Bennett, R.L., Schoof, J.M. and Scott, C.R. (1994) Heterogeneous AVPR2 gene mutations in congenital nephrogenic diabetes insipidus. Am. J. Hum. Genet., 55, 266–277.

Morello, J.P. and Bichet, D.G. (2001) Nephrogenic diabetes insipidus. A. Rev. Physiol., 63, 607–630.

Schöneberg, T., Yun, J., Wenkert, D. and Wess, J. (1996) Functional rescue of mutant V2 vasopressin receptors causing nephrogenic diabetes insipidus by a co-expressed receptor polypeptide. EMBO J., 15, 1283–1291.

Yun, J., Schöneberg, T., Liu, J., Schulz, A., Ecelbarger, C.A., Promeneur, D., Nielsen, S., Sheng, H., Grinberg, A., Deng, C. and Wess, J. (2000) Generation of a mouse model for X-linked nephrogenic diabetes insipidus. J. Clin. Invest., 106, 1361–1371.

Schulz, A., Sangkuhl, K., Lennert, T., Wigger, M., Price, D.A., Nuuja, A., Grüters, A., Schultz, G. and Schöneberg, T. (2002) Aminoglycoside pretreatment partially restores the function of truncated V2 vasopressin receptors found in patients with nephrogenic diabetes insipidus. J. Clin. Endocrinol. Metab., 87, 5247–5257.

Sadeghi, H.M., Innamorati, G. and Birnbaumer, M. (1997) Maturation of receptor proteins in eukaryotic expression systems. J. Recept. Signal. Transduct. Res., 17, 433–445.

Howard, M.T., Shirts, B.H., Petros, L.M., Flanigan, K.M., Gesteland, R.F. and Atkins, J.F. (2000) Sequence specificity of aminoglycoside-induced stop codon read through: potential implications for treatment of Duchenne muscular dystrophy. Ann. Neurol., 48, 164–169.

Culbertson, M.R. (1999) RNA surveillance. Unforeseen consequences for gene expression, inherited genetic disorders and cancer. Trends Genet., 15, 74–80.

Oksche, A., Leder, G., Valet, S., Platzer, M., Hasse, K., Geist, S., Krause, G., Rosenthal, A. and Rosenthal, W. (2002) Variant amino acids in the extracellular loops of murine and human vasopressin V2 receptors account for differences in cell surface expression and ligand affinity. Mol. Endocrinol., 16, 799–813.

Van den Veyver, I.B. (2001) Skewed X inactivation in X-linked disorders. Semin. Reprod. Med., 19, 183–191.

Mooren, F.C. and Kinne, R.K.H. (1994) Intracellular calcium in primary cultures of rat inner medullary collecting duct cells during variations of extracellular osmolality. Pflügers Arch., 42, 463–472.

Wilschanski, M., Famini, C., Blau, H., Rivlin, J., Augarten, A., Avital, A., Kerem, B. and Kerem, E. (2000) A pilot study of the effect of gentamicin on nasal potential difference measurements in cystic fibrosis patients carrying stop mutations. Am. J. Respir. Crit. Care Med., 161, 860–865.

Grayson, C., Chapple, J.P., Willison, K.R., Webster, A.R., Hardcastle, A.J. and Cheetham, M.E. (2002) In vitro analysis of aminoglycoside therapy for the Arg120stop nonsense mutation in RP2 patients. J. Med. Genet., 39, 62–67.

Keeling, K.M., Brooks, D.A., Hopwood, J.J., Li, P., Thompson, J.N. and Bedwell, D.M. (2001) Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum. Mol. Genet., 10, 291–299.

Sleat, D.E., Sohar, I., Gin, R.M. and Lobel, P. (2001) Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis. Eur. J. Paediatr. Neurol., 5, 57–62.

Wilschanski, M., Yahav, Y., Yaacov, Y., Blau, H., Bentur, L., Rivlin, J., Aviram, M., Bdolah-Abram, T., Bebok, Z., Shushi, L. et al. (2003) Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. New Engl. J. Med., 349, 1433–1441.

Manuvakhova, M., Keeling, K. and Bedwell, D.M. (2000) Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA, 6, 1044–1055.

Namy, O., Hatin, I. and Rousset, J.P. (2001) Impact of the six nucleotides downstream of the stop codon on translation termination. EMBO Rep., 2, 787–793.

La Rocca, P.T., Baker, F., Frantz, J.D., Szot, R.J., Black, H.E. and Schwartz, E. (1985) Skin and mucous membrane ulceration in beagle dogs following oral dosing with an experimental aminoglycoside antibiotic. Fundam. Appl. Toxicol., 5, 986–990.

Keeling, K.M. and Bedwell, D.M. (2002) Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J. Mol. Med.,80, 367–376.

Salomon, Y., Londos, C. and Rodbell, M. (1974) A highly sensitive adenylate cyclase assay. Anal. Biochem., 58, 541–548.